about
Accurate prediction of response to endocrine therapy in breast cancer patients: current and future biomarkersCorrecting for intra-experiment variation in Illumina BeadChip data is necessary to generate robust gene-expression profilesA gene on the HER2 amplicon, C35, is an oncogene in breast cancer whose actions are prevented by inhibition of SykDirect integration of intensity-level data from Affymetrix and Illumina microarrays improves statistical power for robust reanalysis.Use of expressed sequence tag analysis and cDNA microarrays of the filamentous fungus Aspergillus nidulans.The removal of multiplicative, systematic bias allows integration of breast cancer gene expression datasets - improving meta-analysis and prediction of prognosis.Biomarkers of dietary energy restriction in women at increased risk of breast cancer.Transcriptome analysis of recombinant protein secretion by Aspergillus nidulans and the unfolded-protein response in vivo.An in vitro model that recapitulates the epithelial to mesenchymal transition (EMT) in human breast cancer.Sprouty 2 is an independent prognostic factor in breast cancer and may be useful in stratifying patients for trastuzumab therapyCyclin D1, Id1 and EMT in breast cancer.Dynamic changes in gene expression in vivo predict prognosis of tamoxifen-treated patients with breast cancer.GnRH receptor activation competes at a low level with growth signaling in stably transfected human breast cell lines.Relative impact of key sources of systematic noise in Affymetrix and Illumina gene-expression microarray experiments.The embryonic transcription cofactor LBH is a direct target of the Wnt signaling pathway in epithelial development and in aggressive basal subtype breast cancersGlutamic protease distribution is limited to filamentous fungi.Down-regulation of the oncogene cyclin D1 increases migratory capacity in breast cancer and is linked to unfavorable prognostic features.Nuclear FAK controls chemokine transcription, Tregs, and evasion of anti-tumor immunity.PIK3CA genotype and a PIK3CA mutation-related gene signature and response to everolimus and letrozole in estrogen receptor positive breast cancerTranscriptionally repressed genes become aberrantly methylated and distinguish tumors of different lineages in breast cancer.Wnt pathway activity in breast cancer sub-types and stem-like cellsDecreased expression of Yes-associated protein is associated with outcome in the luminal A breast cancer subgroup and with an impaired tamoxifen response.Increased STAT1 signaling in endocrine-resistant breast cancer.High-throughput genomic technology in research and clinical management of breast cancer. Exploiting the potential of gene expression profiling: is it ready for the clinic?Defining the molecular response to trastuzumab, pertuzumab and combination therapy in ovarian cancer.The T box transcription factor TBX2 promotes epithelial-mesenchymal transition and invasion of normal and malignant breast epithelial cells.Anti-estrogen Resistance in Human Breast Tumors Is Driven by JAG1-NOTCH4-Dependent Cancer Stem Cell Activity.FRMD4A upregulation in human squamous cell carcinoma promotes tumor growth and metastasis and is associated with poor prognosis.Targeting of Rac GTPases blocks the spread of intact human breast cancer.Mechanisms of Disease: prediction and prevention of breast cancer--cellular and molecular interactions.Tissue of origin determines cancer-associated CpG island promoter hypermethylation patternsTranscript and protein profiling identifies signaling, growth arrest, apoptosis, and NF-κB survival signatures following GNRH receptor activation.Origins of breast cancer subtypes and therapeutic implications.Intermittent energy restriction induces changes in breast gene expression and systemic metabolismIdentification of novel pathways linking epithelial-to-mesenchymal transition with resistance to HER2-targeted therapy.Tumour sampling method can significantly influence gene expression profiles derived from neoadjuvant window studies.The origin of estrogen receptor alpha-positive and alpha-negative breast cancer.Low PIP4K2B expression in human breast tumors correlates with reduced patient survival: A role for PIP4K2B in the regulation of E-cadherin expression.A differential role for CXCR4 in the regulation of normal versus malignant breast stem cell activity.WT1 expression in breast cancer disrupts the epithelial/mesenchymal balance of tumour cells and correlates with the metabolic response to docetaxel.
P50
Q28069856-ED34027F-651F-47F6-9123-7BE64D18D351Q30493843-3B949E13-F348-4B54-B823-F09DE6D70346Q30496002-B23CDEC2-F11E-4EE8-97F4-43D55AA80DCDQ30558563-715EAD79-49FC-443A-9DE9-A1971B0CEA78Q31036677-CA3C719F-B80A-48A7-95A3-7E7227B3F394Q33370712-21A780CA-D741-4D10-A7A6-77C9C222E812Q33490898-A52692D1-AEFC-4D98-ADEE-D7D51606DB8FQ33769853-139591D5-D29D-4317-A4E4-1A290985E0E7Q33828295-6961DE47-8D3A-4BFB-92DF-08842E596BB2Q34016357-1C3188B3-6BBE-4CD6-BEA5-13523016781EQ34034112-16BE1F00-6FAD-4905-95BA-469EBEE8EB34Q34048134-1BC9B839-6296-465D-BD31-BFD0F93264A8Q34066386-84DC4A8B-3465-464D-9072-D0491423740DQ34088518-EA5E7E25-9D38-47E7-8FE8-C7574E07E75DQ34119756-E2DE7E87-7257-44E1-8159-7C9E5A985475Q34353450-EE5214DE-195F-469A-9CF4-4739574A76B2Q34358413-EB380913-2C63-47DB-A5D0-8C453F6A7A76Q34495723-2CE2C5CA-773D-4A9E-8311-E15D63BB5A18Q34542434-93830638-9830-4D6A-9696-ECB31E0B63E3Q34694010-3A751D5C-B8A2-45B3-A11E-402EAF6C13C9Q34826223-5ABEDDEA-B4DC-4166-A25C-1AC7A5BECC40Q35100037-62411DC0-1D14-4E84-996F-4B8B44D13211Q35146693-7CB70D58-03CF-4CA2-9647-BDE5055A7A38Q35605840-49106113-AFA0-49E3-A9FE-262B04703C4EQ35999582-92F7D609-1F8B-43B3-8688-2669E68E404BQ36109766-C9F0E7C5-DA47-4755-B699-A8C0A027B847Q36123897-D56D5A09-B308-4791-BBFD-48908467D8B2Q36193482-54536816-060B-4AA8-B376-996DA02D9797Q36234042-30177D97-3862-420F-B51B-4353CC0764A8Q36337987-C691588C-E3AC-453A-99EE-23F2C231309EQ36378085-82EF0C3D-F0A3-4D83-8232-4B0F836EA53DQ36613911-1E090118-48E6-4DD1-912F-7E39A21AA127Q36922916-73336C71-72BE-4684-8B77-C36C7EF38F05Q36945226-E9B3E4AE-C73D-4650-A52A-925015A36948Q36998301-A227D3AC-A06F-4E0B-87A9-DF96C3FA1E93Q37072929-FD3E270C-3F10-4E32-9DAF-B2BA949BC662Q37170467-C5FF64AC-B118-497A-847D-E2D744B13826Q37660237-726EA183-BC21-4184-9640-0AE790AB57C7Q37718430-7E973F72-0357-43ED-859A-194FBFA98F0AQ37721627-170727AA-EE53-4D3C-B45A-3AE4B53EEF66
P50
description
hulumtues
@sq
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Andrew H Sims
@nl
Andrew H Sims
@sl
Andrew H. Sims
@en
Andrew H. Sims
@es
type
label
Andrew H Sims
@nl
Andrew H Sims
@sl
Andrew H. Sims
@en
Andrew H. Sims
@es
prefLabel
Andrew H Sims
@nl
Andrew H Sims
@sl
Andrew H. Sims
@en
Andrew H. Sims
@es
P1053
E-4819-2012
P106
P1153
7102763208
P21
P2798
P31
P3829
P496
0000-0001-9082-3665